This segment focuses on the research, development, and commercialization of respiratory medicines, including RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA. Research and development activities include clinical trials and collaborations with Glaxo Group Limited for long-acting beta2 agonist (LABA) products. The segment utilizes advanced inhaled drug delivery technologies and focuses on treating chronic obstructive pulmonary disease (COPD) and asthma. Patient impact is significant, improving lung function and quality of life for millions. Market positioning is strong due to established partnerships and approved products. Future opportunities include expanding the product portfolio and exploring new respiratory therapies. Regulatory aspects involve FDA approvals and ongoing clinical studies. This segment is a core area of Innoviva's business, leveraging its expertise in inhaled respiratory medicine.

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, focuses on delivering innovative therapies in critical care and infectious diseases. This segment is involved in the development and commercialization of therapies such as Zoliflodacin, a first-in-class oral antibiotic for uncomplicated gonorrhea. Research and development activities include clinical trials and collaborations with organizations like GARDP. The segment utilizes advanced pharmaceutical technologies to address unmet medical needs in critical care and infectious diseases. Patient impact is significant, offering new treatment options for serious infections. Market positioning is enhanced through strategic partnerships and FDA approvals. Future opportunities include expanding the product pipeline and entering new therapeutic areas. Regulatory aspects involve FDA approvals and adherence to stringent clinical trial protocols. This segment represents Innoviva's commitment to addressing critical healthcare challenges.